https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659339/fda-up-close-and-personal-a-banker-s-recalibrationhttps://www.biocentury.com/article/659339/fda-up-close-and-personal-a-banker-s-recalibration?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYFDA, UP CLOSE AND PERSONAL: A BANKER’S RECALIBRATIONA former agency advisor’s view from inside FDA: What industry often misreads as dysfunction is rooted in caution, independence and process disciplineThu, 30 Apr 2026 17:49:13 -0700https://www.biocentury.com/article/659341/raising-the-bar-on-causal-biology-syncona-s-chris-hollowoodhttps://www.biocentury.com/article/659341/raising-the-bar-on-causal-biology-syncona-s-chris-hollowood?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONRAISING THE BAR ON CAUSAL BIOLOGY — SYNCONA’S CHRIS HOLLOWOODHow evolving discovery, and a strategic pivot, are driving Syncona’s investments thesis on gene therapies and elsewhereThu, 30 Apr 2026 17:01:22 -0700https://www.biocentury.com/article/659337/galapagos-spinout-coultreon-draws-125m-to-test-sik3-inhibitor-venture-reporthttps://www.biocentury.com/article/659337/galapagos-spinout-coultreon-draws-125m-to-test-sik3-inhibitor-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEGALAPAGOS SPINOUT COULTREON DRAWS $125M TO TEST SIK3 INHIBITOR: VENTURE REPORTPlus: Pair of European microbiome companies draw rounds; Apuri backs Sigmeta; and moreThu, 30 Apr 2026 14:39:41 -0700https://www.biocentury.com/article/659214/science-spotlight-making-in-vivo-car-t-less-immunogenichttps://www.biocentury.com/article/659214/science-spotlight-making-in-vivo-car-t-less-immunogenic?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MAKING IN VIVO CAR T LESS IMMUNOGENICPlus: BACH1 skews neuronal fate in Down syndrome, and optimized prime editors drive large genomic insertionsThu, 30 Apr 2026 14:30:51 -0700https://www.biocentury.com/article/659327/tiny-biotech-s-experience-raises-questions-about-fda-s-rare-disease-policieshttps://www.biocentury.com/article/659327/tiny-biotech-s-experience-raises-questions-about-fda-s-rare-disease-policies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTINY BIOTECH’S EXPERIENCE RAISES QUESTIONS ABOUT FDA’S RARE DISEASE POLICIESGrace Science says it has been shut out of plausible mechanism framework, denied flexibility on CMC requirementsWed, 29 Apr 2026 15:11:29 -0700https://www.biocentury.com/article/659321/in-chiesi-s-biggest-m-a-deal-yet-pharma-buys-hae-company-kalvistahttps://www.biocentury.com/article/659321/in-chiesi-s-biggest-m-a-deal-yet-pharma-buys-hae-company-kalvista?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSIN CHIESI’S BIGGEST M&A DEAL YET, PHARMA BUYS HAE COMPANY KALVISTAItalian company adds another rare disease asset via $1.9B takeoutWed, 29 Apr 2026 14:48:39 -0700https://www.biocentury.com/article/659325/a-year-after-tourette-s-readout-teva-pays-700m-up-front-for-vc-backed-emalexhttps://www.biocentury.com/article/659325/a-year-after-tourette-s-readout-teva-pays-700m-up-front-for-vc-backed-emalex?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSA YEAR AFTER TOURETTE’S READOUT, TEVA PAYS $700M UP FRONT FOR VC-BACKED EMALEXSeeing potential growth driver, pharma adds ‘NDA-ready’ asset for pediatric neurological disorderWed, 29 Apr 2026 14:38:50 -0700https://www.biocentury.com/article/659324/prvs-still-pricey-despite-renewalhttps://www.biocentury.com/article/659324/prvs-still-pricey-despite-renewal?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEPRVS STILL PRICEY DESPITE RENEWALTwo priority review vouchers have sold since the rare pediatric program was extendedWed, 29 Apr 2026 13:49:41 -0700https://www.biocentury.com/article/659269/aurora-making-bespoke-base-editing-commercially-viablehttps://www.biocentury.com/article/659269/aurora-making-bespoke-base-editing-commercially-viable?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEAURORA: MAKING BESPOKE BASE EDITING COMMERCIALLY VIABLEBacked by $16 million in seed funding from Menlo, Aurora is starting with PKU as proving groundTue, 28 Apr 2026 16:06:42 -0700https://www.biocentury.com/article/659285/kurma-s-latest-fundraise-highlights-challenges-for-early-stage-vcshttps://www.biocentury.com/article/659285/kurma-s-latest-fundraise-highlights-challenges-for-early-stage-vcs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKURMA’S LATEST FUNDRAISE HIGHLIGHTS CHALLENGES FOR EARLY-STAGE VCSEuropean investor closes new fund at €215M — a 34% increase over its predecessor — with half earmarked for company creationTue, 28 Apr 2026 15:33:48 -0700https://www.biocentury.com/article/659306/new-targets-uncovered-at-aacrhttps://www.biocentury.com/article/659306/new-targets-uncovered-at-aacr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONNEW TARGETS UNCOVERED AT AACR BioCentury’s list of 172 new targets from this year’s American Association for Cancer Research abstractsTue, 28 Apr 2026 15:10:08 -0700https://www.biocentury.com/article/659287/lilly-s-deal-spree-continues-with-ajax-takeout-deals-reporthttps://www.biocentury.com/article/659287/lilly-s-deal-spree-continues-with-ajax-takeout-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY’S DEAL SPREE CONTINUES WITH AJAX TAKEOUT: DEALS REPORTPlus: Sun buying Organon; BeOne in trispecifics deal with Huahui; and moreMon, 27 Apr 2026 18:23:37 -0700https://www.biocentury.com/article/659293/intellia-s-late-stage-win-tees-up-market-test-case-for-in-vivo-crisprhttps://www.biocentury.com/article/659293/intellia-s-late-stage-win-tees-up-market-test-case-for-in-vivo-crispr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTINTELLIA’S LATE-STAGE WIN TEES UP MARKET TEST CASE FOR IN VIVO CRISPRBioCentury’s clinical report April 21-27Mon, 27 Apr 2026 18:21:18 -0700https://www.biocentury.com/article/659296/immune-enhancing-mechanisms-define-new-oncology-targets-at-aacrhttps://www.biocentury.com/article/659296/immune-enhancing-mechanisms-define-new-oncology-targets-at-aacr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONIMMUNE-ENHANCING MECHANISMS DEFINE NEW ONCOLOGY TARGETS AT AACRBioCentury identified 172 new targets at AACR 2026Mon, 27 Apr 2026 18:18:34 -0700https://www.biocentury.com/article/659298/new-targets-at-aacr-biopharma-deals-kurma-fund-a-biocentury-podcasthttps://www.biocentury.com/article/659298/new-targets-at-aacr-biopharma-deals-kurma-fund-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNEW TARGETS AT AACR, BIOPHARMA DEALS, KURMA FUND — A BIOCENTURY PODCAST Target discovery, pan-RAS ADCs at the American Association for Cancer ResearchMon, 27 Apr 2026 17:40:10 -0700https://www.biocentury.com/article/659291/new-data-suggest-oruka-s-il-23-mab-could-be-competitive-in-psoriasishttps://www.biocentury.com/article/659291/new-data-suggest-oruka-s-il-23-mab-could-be-competitive-in-psoriasis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTENEW DATA SUGGEST ORUKA’S IL-23 MAB COULD BE COMPETITIVE IN PSORIASIS Phase IIa results show high PASI 100 rates for half-life-extended ORKA-001, but durability and quality-of-life data still pendingMon, 27 Apr 2026 16:40:11 -0700https://www.biocentury.com/article/659276/inventiva-reloads-c-suite-as-it-looks-to-readouthttps://www.biocentury.com/article/659276/inventiva-reloads-c-suite-as-it-looks-to-readout?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSINVENTIVA RELOADS C-SUITE AS IT LOOKS TO READOUTNew CEO for Santhera and moreFri, 24 Apr 2026 16:55:34 -0700https://www.biocentury.com/article/659275/ema-s-chmp-backs-sanofi-btk-inhibitor-rebuffed-by-fdahttps://www.biocentury.com/article/659275/ema-s-chmp-backs-sanofi-btk-inhibitor-rebuffed-by-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEEMA’S CHMP BACKS SANOFI BTK INHIBITOR REBUFFED BY FDAPlus positive opinions in April on Fri, 24 Apr 2026 16:53:10 -0700https://www.biocentury.com/article/659271/nektar-parlays-alopecia-readout-into-374m-follow-on-public-equity-reporthttps://www.biocentury.com/article/659271/nektar-parlays-alopecia-readout-into-374m-follow-on-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCENEKTAR PARLAYS ALOPECIA READOUT INTO $374M FOLLOW-ON: PUBLIC EQUITY REPORTPlus: AnaptysBio’s autoimmune spinout First Tracks Bio arrives on NASDAQ; and moreFri, 24 Apr 2026 15:40:55 -0700https://www.biocentury.com/article/659261/the-podcaster-to-policy-pathway-poses-risks-to-patients-innovationhttps://www.biocentury.com/article/659261/the-podcaster-to-policy-pathway-poses-risks-to-patients-innovation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYTHE PODCASTER-TO-POLICY PATHWAY POSES RISKS TO PATIENTS, INNOVATIONThe Trump administration’s moves on peptides and psychedelics should alarm everyone, not least small biotechsFri, 24 Apr 2026 12:04:09 -0700https://www.biocentury.com/article/659256/milestones-mounting-in-biotech-m-ahttps://www.biocentury.com/article/659256/milestones-mounting-in-biotech-m-a?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMILESTONES MOUNTING IN BIOTECH M&ASince mid-2024 55% of deals $500M+ had CVRs or other contingent paymentsThu, 23 Apr 2026 17:35:26 -0700https://www.biocentury.com/article/659251/cell-therapy-phase-i-activity-accelerates-on-china-surgehttps://www.biocentury.com/article/659251/cell-therapy-phase-i-activity-accelerates-on-china-surge?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTECELL THERAPY PHASE I ACTIVITY ACCELERATES ON CHINA SURGEPhase I cell therapy starts outpaced other new modalities in 2021-25, with China biotechs driving the growthThu, 23 Apr 2026 16:17:51 -0700https://www.biocentury.com/article/659249/vcs-back-tortugas-to-advance-eisai-hansoh-neurology-compounds-venture-reporthttps://www.biocentury.com/article/659249/vcs-back-tortugas-to-advance-eisai-hansoh-neurology-compounds-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEVCS BACK TORTUGAS TO ADVANCE EISAI, HANSOH NEUROLOGY COMPOUNDS: VENTURE REPORTPlus: Flagship’s Serif seeks ‘Modified DNA’ therapies; gene therapy play Ray’s raise; new funds for Kurma and Lumira; and moreThu, 23 Apr 2026 15:13:32 -0700https://www.biocentury.com/article/659259/pan-ras-inhibitor-adcs-emerge-at-aacr-2026https://www.biocentury.com/article/659259/pan-ras-inhibitor-adcs-emerge-at-aacr-2026?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPAN-RAS INHIBITOR ADCS EMERGE AT AACR 2026At least four companies are testing whether antibody conjugation can preserve pan-RAS efficacy while reducing systemic toxicityThu, 23 Apr 2026 13:52:38 -0700https://www.biocentury.com/article/659235/aacr-data-and-de-riskinghttps://www.biocentury.com/article/659235/aacr-data-and-de-risking?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAACR: DATA AND DE-RISKINGIQVIA CMO Kyle Bryan’s take on what the conference signals about where technology innovation is headed in oncologyWed, 22 Apr 2026 18:16:24 -0700https://www.biocentury.com/article/659232/reese-retiring-after-two-decades-at-amgenhttps://www.biocentury.com/article/659232/reese-retiring-after-two-decades-at-amgen?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSREESE RETIRING AFTER TWO DECADES AT AMGENIncoming BioMarin chair Clark has Genentech rootsWed, 22 Apr 2026 17:57:28 -0700https://www.biocentury.com/article/659233/t-cell-engagers-confront-new-rules-in-autoimmunityhttps://www.biocentury.com/article/659233/t-cell-engagers-confront-new-rules-in-autoimmunity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTT CELL ENGAGERS CONFRONT NEW RULES IN AUTOIMMUNITYAs developers reposition B cell-depleting bispecifics, the key questions are how deeply to deplete, how to dose for safety, and which patients to treatWed, 22 Apr 2026 17:16:26 -0700https://www.biocentury.com/article/659216/science-spotlight-csf-biomarker-discriminates-between-ftld-pathologieshttps://www.biocentury.com/article/659216/science-spotlight-csf-biomarker-discriminates-between-ftld-pathologies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: CSF BIOMARKER DISCRIMINATES BETWEEN FTLD PATHOLOGIESPlus: Reducing on-target side effects of CB1 agonists and a cell-type-specific mitochondrial delivery systemWed, 22 Apr 2026 11:28:40 -0700https://www.biocentury.com/article/659197/multi-regional-trials-have-yet-to-become-the-normhttps://www.biocentury.com/article/659197/multi-regional-trials-have-yet-to-become-the-norm?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMULTI-REGIONAL TRIALS HAVE YET TO BECOME THE NORMBio€quity Europe preview: Scene Setter analyzes single- vs. multi-regional clinical trialsTue, 21 Apr 2026 18:23:38 -0700https://www.biocentury.com/article/659168/elevara-targeting-a-non-immune-driver-of-rheumatoid-arthritishttps://www.biocentury.com/article/659168/elevara-targeting-a-non-immune-driver-of-rheumatoid-arthritis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEELEVARA: TARGETING A NON-IMMUNE DRIVER OF RHEUMATOID ARTHRITISU.K. biotech aims to deliver CDK4/6 inhibitor with wider therapeutic window than cancer therapies in the classTue, 21 Apr 2026 17:58:41 -0700https://www.biocentury.com/article/659185/recent-megadeals-reset-the-high-end-of-private-biotech-m-ahttps://www.biocentury.com/article/659185/recent-megadeals-reset-the-high-end-of-private-biotech-m-a?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTERECENT MEGADEALS RESET THE HIGH END OF PRIVATE BIOTECH M&ATwo biggest upfront payments for venture-backed biotech takeouts came this month; Kelonia’s was 65x the capital it raisedTue, 21 Apr 2026 15:23:54 -0700https://www.biocentury.com/article/659195/neurona-takeout-adds-to-ucb-s-epilepsy-portfolio-deals-reporthttps://www.biocentury.com/article/659195/neurona-takeout-adds-to-ucb-s-epilepsy-portfolio-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNEURONA TAKEOUT ADDS TO UCB’S EPILEPSY PORTFOLIO: DEALS REPORTPlus: Lilly buys dual-payload ADC developer CrossBridge; Kelonia takeout is latest in vivo CAR T acquisition; and moreTue, 21 Apr 2026 14:20:14 -0700https://www.biocentury.com/article/659181/trump-s-psychedelic-order-tests-review-normshttps://www.biocentury.com/article/659181/trump-s-psychedelic-order-tests-review-norms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTRUMP’S PSYCHEDELIC ORDER TESTS REVIEW NORMSAtypical policymaking process raises concerns about rigor, precedent and politicization of regulatory decisionsMon, 20 Apr 2026 18:39:32 -0700https://www.biocentury.com/article/659183/kelonia-kailera-pyschedelics-and-t-cell-engagers-a-biocentury-podcasthttps://www.biocentury.com/article/659183/kelonia-kailera-pyschedelics-and-t-cell-engagers-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSKELONIA, KAILERA, PYSCHEDELICS AND T CELL ENGAGERS — A BIOCENTURY PODCASTLilly’s $3.25B deal for CAR T company, obesity play’s bumper IPO and moreMon, 20 Apr 2026 17:54:07 -0700https://www.biocentury.com/article/659180/nektar-s-phase-ii-alopecia-extension-reveals-late-responders-to-il-2-therapyhttps://www.biocentury.com/article/659180/nektar-s-phase-ii-alopecia-extension-reveals-late-responders-to-il-2-therapy?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNEKTAR’S PHASE II ALOPECIA EXTENSION REVEALS LATE RESPONDERS TO IL-2 THERAPYBioCentury’s Clinical Report April 15–20Mon, 20 Apr 2026 17:32:47 -0700https://www.biocentury.com/article/659178/from-brushes-with-insolvency-to-record-3-25b-takeout-kelonia-broadens-lilly-s-in-vivo-car-t-pipelinehttps://www.biocentury.com/article/659178/from-brushes-with-insolvency-to-record-3-25b-takeout-kelonia-broadens-lilly-s-in-vivo-car-t-pipeline?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSFROM BRUSHES WITH INSOLVENCY TO RECORD $3.25B TAKEOUT, KELONIA BROADENS LILLY’S IN VIVO CAR T PIPELINELargest M&A deal ever for a private, venture-backed biopharma generates huge return for Venrock, fellow investorsMon, 20 Apr 2026 15:38:41 -0700https://www.biocentury.com/article/659175/moses-named-chair-of-grey-wolf-zong-joining-harbour-biomedhttps://www.biocentury.com/article/659175/moses-named-chair-of-grey-wolf-zong-joining-harbour-biomed?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSMOSES NAMED CHAIR OF GREY WOLF; ZONG JOINING HARBOUR BIOMEDRemembering a trio of European pioneersFri, 17 Apr 2026 16:37:04 -0700https://www.biocentury.com/article/659173/fda-s-budget-proposal-include-policy-wish-listhttps://www.biocentury.com/article/659173/fda-s-budget-proposal-include-policy-wish-list?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA’S BUDGET PROPOSAL INCLUDE POLICY WISH LISTAgency seeking to make pediatric priority review vouchers permanent, boot industry off advisory committeesFri, 17 Apr 2026 16:34:49 -0700https://www.biocentury.com/article/659170/kailera-obesity-play-with-china-roots-upsizes-ipo-putting-it-among-biggest-ever-public-equity-reporthttps://www.biocentury.com/article/659170/kailera-obesity-play-with-china-roots-upsizes-ipo-putting-it-among-biggest-ever-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKAILERA, OBESITY PLAY WITH CHINA ROOTS, UPSIZES IPO, PUTTING IT AMONG BIGGEST EVER: PUBLIC EQUITY REPORTPlus: Tools company Alamar lists on NASDAQ as queue swells; Revolution’s massive follow-on; and moreFri, 17 Apr 2026 14:18:38 -0700https://www.biocentury.com/article/659161/aacr-spotlights-dual-payload-adcs-as-the-modality-nears-the-clinichttps://www.biocentury.com/article/659161/aacr-spotlights-dual-payload-adcs-as-the-modality-nears-the-clinic?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAACR SPOTLIGHTS DUAL-PAYLOAD ADCS AS THE MODALITY NEARS THE CLINICMore than 40 abstracts showcase designs intended to counter payload resistance and tumor heterogeneityFri, 17 Apr 2026 13:19:51 -0700https://www.biocentury.com/article/659150/forbion-s-slootweg-on-europe-s-funding-environmenthttps://www.biocentury.com/article/659150/forbion-s-slootweg-on-europe-s-funding-environment?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEFORBION’S SLOOTWEG ON EUROPE’S FUNDING ENVIRONMENTSlootweg also details Forbion’s meteoric rise to become the largest independent European VC, and hunting for new assets in AsiaFri, 17 Apr 2026 09:38:42 -0700https://www.biocentury.com/article/659151/autoimmune-t-cell-engagers-diverge-from-their-oncology-rootshttps://www.biocentury.com/article/659151/autoimmune-t-cell-engagers-diverge-from-their-oncology-roots?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAUTOIMMUNE T CELL ENGAGERS DIVERGE FROM THEIR ONCOLOGY ROOTSAs the pipeline expands, developers are splitting between modified cancer assets and autoimmune-first formatsThu, 16 Apr 2026 16:54:33 -0700https://www.biocentury.com/article/659007/scala-biodesign-embedding-biologic-design-into-pharma-r-d-workflowshttps://www.biocentury.com/article/659007/scala-biodesign-embedding-biologic-design-into-pharma-r-d-workflows?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILESCALA BIODESIGN: EMBEDDING BIOLOGIC DESIGN INTO PHARMA R&D WORKFLOWSIsraeli biotech’s $16M series A will support global expansion of AI biologics platform ScalaOSThu, 16 Apr 2026 15:58:40 -0700https://www.biocentury.com/article/659160/now-in-clinic-neomorph-heads-into-aacr-with-100m-series-b-venture-reporthttps://www.biocentury.com/article/659160/now-in-clinic-neomorph-heads-into-aacr-with-100m-series-b-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCENOW IN CLINIC, NEOMORPH HEADS INTO AACR WITH $100M SERIES B: VENTURE REPORTPlus: Rounds for Terremoto, Adcendo, Beeline and moreThu, 16 Apr 2026 15:35:51 -0700https://www.biocentury.com/article/659153/fda-s-peptide-plans-reinforce-concerns-about-ideology-politics-influencing-its-decisionshttps://www.biocentury.com/article/659153/fda-s-peptide-plans-reinforce-concerns-about-ideology-politics-influencing-its-decisions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA’S PEPTIDE PLANS REINFORCE CONCERNS ABOUT IDEOLOGY, POLITICS INFLUENCING ITS DECISIONS Agency moves toward relaxing restrictions on untested peptidesWed, 15 Apr 2026 17:53:05 -0700https://www.biocentury.com/article/659155/structure-hires-metsera-alum-lang-as-coo-general-counselhttps://www.biocentury.com/article/659155/structure-hires-metsera-alum-lang-as-coo-general-counsel?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSSTRUCTURE HIRES METSERA ALUM LANG AS COO, GENERAL COUNSELIrish BBB shuttle play Aerska adds chief platform officers, Evotec hires COO, and more Wed, 15 Apr 2026 17:35:11 -0700https://www.biocentury.com/article/659140/a-32-year-look-at-biotech-s-capital-expansionhttps://www.biocentury.com/article/659140/a-32-year-look-at-biotech-s-capital-expansion?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEA 32-YEAR LOOK AT BIOTECH’S CAPITAL EXPANSIONHalf of all biotech equity capital raised since 1994 came in the last eight yearsWed, 15 Apr 2026 13:23:03 -0700https://www.biocentury.com/article/659119/u-s-still-top-spot-for-phase-i-trials-but-china-leads-in-i-i-metabolic-diseasehttps://www.biocentury.com/article/659119/u-s-still-top-spot-for-phase-i-trials-but-china-leads-in-i-i-metabolic-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEU.S. STILL TOP SPOT FOR PHASE I TRIALS, BUT CHINA LEADS IN I&I, METABOLIC DISEASEAn analysis of Phase I trials from 2021-25, across disease categoriesWed, 15 Apr 2026 10:05:00 -0700https://www.biocentury.com/article/659116/remembering-sofinnova-s-denis-lucquin-father-of-french-biotechhttps://www.biocentury.com/article/659116/remembering-sofinnova-s-denis-lucquin-father-of-french-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSREMEMBERING SOFINNOVA’S DENIS LUCQUIN, FATHER OF FRENCH BIOTECHInvestor helped build ecosystem in France and beyondTue, 14 Apr 2026 18:11:23 -0700https://www.biocentury.com/article/659144/novartis-narasimhan-joins-anthropic-boardhttps://www.biocentury.com/article/659144/novartis-narasimhan-joins-anthropic-board?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNOVARTIS’ NARASIMHAN JOINS ANTHROPIC BOARDBioCentury’s latest roundup of management changes across the biotech industryTue, 14 Apr 2026 17:42:33 -0700